Le Lézard
Classified in: Health
Subject: SVY

Global Osteoarthritis Treatment Market to Reach US$ 11,618.6 Mn by 2025 - Persistence Market Research


NEW YORK, March 21, 2018 /PRNewswire/ --

Willingness of Patients to Opt for Treatments in Developed Regions to Boost Revenue Growth of the Global Osteoarthritis Treatment Market

Persistence Market Research (PMR) has published a new research report on the osteoarthritis treatment market titled "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)." An alarming rise in the number of osteoarthritis cases is the result of a growing geriatric population worldwide.

     (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO )

In order to cater to the needs of the rapidly increasing geriatric population as well as the female population - given that osteoarthritis prevails mostly among these groups - the manufacturers of osteoarthritis drugs are focusing on research and development to be able to develop better and reliable drugs.

As this disease is not treatable, the market is an ever growing one. In this run, the leading companies are also collaborating with other big companies in order to use their formulas and production equipment.

Global Osteoarthritis Treatment Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/osteoarthritis-market.asp

For instance, in September 2016, Pfizer Inc. completed the acquisition of Medivation, Inc., a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases that have limited treatment options. In this regard, the company also acquired the commercialization and development rights of the late stage small molecules anti-infective business, mainly outside the U.S. from AstraZeneca.

Other companies operating in the market are Johnson & Johnson Services, Inc., Novartis AG, GlaxoSmithKline plc. Abbott Laboratories, and Zimmer Biomet Holdings, Inc., among others.

According to the report, the global osteoarthritis treatment market is expected to register a CAGR of 4.8% from 2017 to 2025. In 2017, the market was valued at US$ 7,969.7 Mn and is expected to rise to a valuation of US$ 11,618.6 Mn by the end of 2025.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/4458

Growing Geriatric Population and Rising Prevalence of Disease to Trigger Adoption 

The prevalence of osteoarthritis is increasing across the globe and it is the major cause of disability, especially among the ageing population. Women are more likely to be affected than men and the prevalence rate progresses with age.

Increasing awareness regarding the risk factors associated with osteoarthritis (such as obesity) among the general population due to government action plans to control the disease is expected to boost the growth of the osteoarthritis treatment market.

However, improvement in healthcare policies in various countries such as the U.S. has resulted in enhanced affordability for various diagnostic and treatment services, which in turn has increased the life expectancy of people. Other dynamics such as the availability of alternative medicines are expected to boost the growth of the market.

 Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/market-research/osteoarthritis-market/toc

Non-availability of Permanent Cure for Osteoarthritis to Restrict Market Growth 

Presently, there is no cure of osteoarthritis but the treatment is aimed to manage the symptoms. Aspects such as lack of awareness regarding risk factors and symptoms of osteoarthritis is expected to restrain the growth of the osteoarthritis treatment market. There is no simple diagnosis available for osteoarthritis.

Diagnosis is based on a variable combination of patient reported symptoms and imaging of the joint. Mostly x-ray is used to diagnose osteoarthritis, but it often does not correlate with other symptoms of osteoarthritis including joint pain.

Get full Report Now https://www.persistencemarketresearch.com/checkout/4458

Persistence Market Research Overview

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: [email protected]

PMR Latest News: https://www.persistencemarketresearch.com/news


These press releases may also interest you

at 17:49
The ALS Association today celebrated the beginning of ALS Awareness Month and the 10th Anniversary of the Ice Bucket Challenge, which inspired the world to join the fight against ALS in the summer of 2014. Throughout May and the summer, the ALS...

at 17:31
White Glove Placement, a leading provider of staffing solutions for healthcare facilities, is proud to announce its "Scoops of Gratitude" Free Ice Cream Truck to celebrate Nurses Week and show appreciation for the dedication and hard work of nurses...

at 17:31
DelveInsight's Opioid Withdrawal...

at 17:30
Two El Camino Health hospitals in the South Bay have earned the highest ranking for patient safety from The Leapfrog Group, a national, not-for-profit, independent evaluator that measures excellence in patient care. This national distinction marks...

at 17:25
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the...

at 17:23
EVP Capital Inc. ("EVP Capital"), a capital pool company ("CPC") listed on the TSX Venture Exchange Inc. (the "Exchange"), is pleased to announce that it has entered into a non-binding letter of intent dated May 1, 2024 (the "LOI") with Sharp Edge...



News published on and distributed by: